GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » EV-to-EBITDA

Oncolytics Biotech (Oncolytics Biotech) EV-to-EBITDA : -2.29 (As of Apr. 27, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oncolytics Biotech's enterprise value is $56.81 Mil. Oncolytics Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.84 Mil. Therefore, Oncolytics Biotech's EV-to-EBITDA for today is -2.29.

The historical rank and industry rank for Oncolytics Biotech's EV-to-EBITDA or its related term are showing as below:

ONCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.44   Med: 0   Max: 0
Current: -2.28

ONCY's EV-to-EBITDA is ranked worse than
100% of 472 companies
in the Biotechnology industry
Industry Median: 9.1 vs ONCY: -2.28

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Oncolytics Biotech's stock price is $1.09. Oncolytics Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.304. Therefore, Oncolytics Biotech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Oncolytics Biotech EV-to-EBITDA Historical Data

The historical data trend for Oncolytics Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech EV-to-EBITDA Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.27 -4.34 -2.16 -3.93 -2.96

Oncolytics Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.93 -2.83 -7.29 -5.39 -2.96

Competitive Comparison of Oncolytics Biotech's EV-to-EBITDA

For the Biotechnology subindustry, Oncolytics Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's EV-to-EBITDA falls into.



Oncolytics Biotech EV-to-EBITDA Calculation

Oncolytics Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=56.810/-24.843
=-2.29

Oncolytics Biotech's current Enterprise Value is $56.81 Mil.
Oncolytics Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncolytics Biotech  (NAS:ONCY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oncolytics Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.09/-0.304
=At Loss

Oncolytics Biotech's share price for today is $1.09.
Oncolytics Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.304.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Oncolytics Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.